Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Tonya Beineman

Nurse Practitioner Fort Smith, AR Nurse Practitioner

NPI 1306957006 CMS profile 10903299

3811 Rogers Ave, Suite A, Fort Smith, AR 72903

Open in the dashboard

General payments

$1,729

188 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Tonya Beineman of Fort Smith, AR is reported in the CMS Open Payments database as having received $1,729 across 188 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 78th percentile of Nurse Practitioner profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $398 28
2024 General $272 25
2023 General $371 46
2022 General $393 46
2021 General $295 43

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Tonya Beineman
  • Nurse Practitioner median
  • Middle half of Nurse Practitioner
  • National median

In program year 2025, general payments to Tonya Beineman were reported at $398. Among 41,044 Nurse Practitioner profiles paid that year, the median was $174 and the middle half received between $55 and $557.

Show as a table
Year Tonya Beineman Nurse Practitioner median Middle half National median
2019 $0 $50 $22–$97 $163
2020 $0 $40 $16–$108 $114
2021 $295 $135 $40–$426 $132
2022 $393 $152 $48–$470 $149
2023 $371 $166 $54–$529 $160
2024 $272 $173 $55–$556 $164
2025 $398 $174 $55–$557 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. ITI, Inc. $879 94 payments
  2. AbbVie, Inc. $448 58 payments
  3. Biohaven Pharmaceuticals, Inc. $169 22 payments
  4. Salix Pharmaceuticals, a division of Bausch Health US, LLC $93 5 payments
  5. Horizon Therapeutics plc $65 4 payments
  6. AstraZeneca Pharmaceuticals LP $18 1 payment
  7. Antares Pharma, Inc. $15 1 payment
  8. Lilly USA, LLC $15 1 payment
  9. CutisPharma, Inc. $14 1 payment
  10. Janssen Pharmaceuticals, Inc $13 1 payment

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $1,720 187 payments
  2. Education $8 1 payment
Products named General payments · program years 2021–2025
  1. CAPLYTA Psychiatry $515 68 payments
  2. CAPLYTA Psychiatry $364 26 payments
  3. VRAYLAR $305 42 payments
  4. NURTEC ODT $169 22 payments
  5. XIFAXAN $93 5 payments
  6. TRULANCE $74 4 payments
  7. QULIPTA $71 6 payments
  8. PENNSAID $65 4 payments
  9. UBRELVY $40 7 payments
  10. BOTOX $20 1 payment
  11. Other $77 6 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 101 drugs

Part D claims

4,680

Median for Nurse Practitioner: 389

Drug cost

$291,858

Median for Nurse Practitioner: $21,885

Branded share of claims

19%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Mounjaro Tirzepatide Brand 58 $68,823
Jardiance Empagliflozin Brand 80 $55,659
Eliquis Apixaban Brand 33 $29,528
Trulicity Dulaglutide Brand 22 $27,306
Ozempic Semaglutide Brand 27 $25,051
Linzess Linaclotide Brand 18 $15,776
Farxiga Dapagliflozin Propanediol Brand 15 $13,773
Xarelto Rivaroxaban Brand 16 $8,564
Synthroid Levothyroxine Sodium Brand 66 $3,887
Levothyroxine Sodium Generic 351 $2,110

The 10 drugs with the highest cost, of 101 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 18 billing codes

Paid by Medicare

$45,251

Of which drugs: $144

Medicare patients

118

Average age 72

Services billed

1,337

89 women, 29 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 64%
Arthritis 43%
Depression 32%
Osteoporosis 26%
Diabetes 25%
Ischemic heart disease 19%
Heart failure 17%
Chronic kidney disease 13%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 24 92 $67
Injection, ceftriaxone sodium, per 250 mg J0696 Office 34 146 $48
Injection, dexamethasone sodium phosphate, 1 mg J1100 Office 24 92 $8

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 6 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
CAPLYTA
  • ITI, Inc. $186
$186 — —
XIFAXAN
  • Salix Pharmaceuticals, a division of Bausch Health US, LLC $28
$28 — —
BREZTRI
  • AstraZeneca Pharmaceuticals LP $18
$18 — —
VRAYLAR
  • AbbVie, Inc. $17
$17 — —
EDARBI
  • CutisPharma, Inc. $14
$14 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 6 in the dashboard with a free account

Records

188 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner in Arkansas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record